OpZira, Inc. Launches to Advance Ophthalmic Diagnostics with Innovative Medical Device Portfolio
OpZira™, Inc., a forward-thinking ophthalmic medical device company founded on a legacy of research excellence, today announced its official formation. OpZira is dedicated to delivering innovative technologies that enhance the detection and monitoring of ocular disease, empowering clinicians with advanced diagnostic tools.
OpZira’s creation follows Alcon’s acquisition of LumiThera (https://www.alcon.com/media-release/alcon-completes-acquisition-lumithera/) and its innovative Valeda® Light Delivery System, the first and only FDA-authorized treatment for dry age-related macular degeneration (AMD). As part of the transaction, LumiThera’s diagnostic product lines were spun off to LumiThera shareholders, leading to the establishment of OpZira, Inc.
OpZira’s product portfolio includes:
- AdaptDx Pro® – A wearable dark adaptometer that leverages AI to ensure a consistent patient experience. Impaired dark adaptation speed, a key early indicator of rod-mediated dysfunction, is often among the first functional signs of retinal disease. AdaptDx Pro is available in the U.S.
- NOVA™ Vision Testing System – A robust electrophysiology platform providing objective assessments of the entire visual and neuro-visual pathway. The Visual Evoked Potential (VEP) module is available in the U.S. and select international markets, while the Electroretinography (ERG) module is available outside the U.S.
“Building on the LumiThera team’s success in developing the Valeda treatment for early to intermediate dry AMD patients, the OpZira technologies may provide early detection and ongoing monitoring which are important for optimizing patient outcomes,” stated Eleonora Lad, MD, PhD, Duke University Medical Center. “Now that there are approved treatment options for dry AMD, having tools that provide objective data to help determine when and how often to treat patients is critical.”
“OpZira was founded to bridge the gap between groundbreaking research and practical clinical tools,” said Clark Tedford, PhD, President & CEO of OpZira. “Our mission is to give eye care professionals the technology they need to detect ocular diseases earlier and monitor them more effectively.”
About OpZira
OpZira, Inc. is a forward-thinking ophthalmic medical device company founded on a legacy of research excellence. The company delivers innovative technologies designed to enhance the detection and monitoring of ocular disease. For more information, visit OpZira.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250903785229/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BTG Bioliquids and NanosTech Partner to Deliver End-to-End Advanced Biofuels Solution3.9.2025 18:19:00 CEST | Press release
BTG Bioliquids BV (BTL), a Netherlands-based leader in fast pyrolysis technology, and NanosTech Technology & Innovations Ltd. (NanosTech), a Canada-based catalyst development and manufacturing company, have signed a Memorandum of Understanding (MOU) to deliver a fully integrated solution to produce advanced, drop-in biofuels. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250903698730/en/ The partnership combines BTL’s proven fast pyrolysis technology, which converts sustainable biomass into bio-oil, with NanosTech’s proprietary Aquaprocessing (AQP) platform, which upgrades even the most challenging bio-oils into refinery-ready feedstocks to produce fuels such as sustainable aviation fuel (SAF), renewable diesel, and marine fuels. The two companies are now actively collaborating to determine the location in Canada and Europe for the new 500-barrel-per-day modular biorefinery system. This system can be deployed near the feeds
Armis Named a Leader in IoT Security Solutions, Q3 2025 Evaluation3.9.2025 15:58:00 CEST | Press release
Recognition follows Armis being named a Leader in Unified Vulnerability Management Solutions evaluation Armis, the cyber exposure management & security company, today announced that it has been named a Leader in The Forrester Wave™: IoT Security Solutions, Q3 2025. This achievement comes on the heels of Armis being named a Leader in The Forrester Wave™: Unified Vulnerability Management Solutions, Q3 2025. In this Forrester Wave™, Armis is ranked a Leader and achieved the highest scores possible in 9 key criteria. According to the report, “Armis’ vision centers on delivering enterprise-wide exposure management that goes beyond IoT and OT devices. Its innovation investments and acquisitions support this goal. Its roadmap aligns with customer priorities while anticipating future needs to ensure the platform evolves alongside its clients. This forward-looking strategy fosters successful adoption and helps customers deploy the Centrix platform successfully.” “We’re proud to once again be re
Rapid Medical™ Surpasses 1,000 Cases With DRIVEWIRE™ 24 in North America and Expands Into Europe With MDR Approval3.9.2025 15:46:00 CEST | Press release
Clinical performance and strong physician demand drive swift uptake and global approval of next-generation access technology Rapid Medical™, a leading developer of active endovascular devices, announces that its DRIVEWIRE™ 24 steerable guidewire has been used in more than 1,000 neurovascular procedures in North America during a limited commercial launch beginning earlier this year. The company also announced receipt of CE Mark under the European Medical Device Regulation (MDR), as presented at the 2025 ESMINT Annual Meeting. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250903530140/en/ “In my experience, the wire provides a unique combination of precision and support that simply hasn’t been possible with conventional technologies,” stated Dr. Erez Nossek, a neurosurgeon at NYU Langone in New York, NY. “It has become a reliable tool that allows us to approach any anatomy with greater efficiency and less time.” As the first
Ondo Finance and Alpaca Collaborate to Tokenize US Stocks and ETFs3.9.2025 15:30:00 CEST | Press release
Bridging traditional finance and on-chain markets, increasing access to high-quality assets Today, Ondo Finance, a leader in blockchain-based financial innovation and tokenized real-world assets, announced the launch of Ondo Global Markets, their platform for tokenized US stocks and ETFs. The platform is powered by a strategic integration with Alpaca, a self-clearing broker-dealer and brokerage infrastructure API for stocks, ETFs, and options trading, as well as crypto. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250903244835/en/ Ondo Finance and Alpaca collaborate to tokenize US stocks and ETFs; bridging traditional finance and on-chain markets, increasing access to high-quality assets. According to a McKinsey report, the tokenized market capitalization could reach around $2 trillion by 2030 across a variety of asset classes. This expected rise in market demand for tokenized assets, like US stocks and ETFs, comes as glob
TON Strategy Company Approves $250 Million Stock Repurchase Program After Ticker Change3.9.2025 15:20:00 CEST | Press release
Open-ended stock repurchase program unanimously approved by the board Aims to create shareholder value by growing Net Asset Value per Share (NAV/share), including in times of heightened volatility TON Strategy Company (formerly Verb Technology Company Inc.) (Nasdaq: TONX) (the “Company”), a digital asset treasury company committed to holding Toncoin ($TON), today announced that its Board of Directors has unanimously approved a stock repurchase program authorizing the Company to repurchase up to $250 million of its common stock. Under the program, repurchases may be made from time to time in open market transactions or through other means in accordance with applicable securities laws. The timing, number of shares of common stock repurchased, and price will depend on a variety of factors including liquidity, market conditions, share price, and other considerations. The program does not obligate the Company to acquire any specific number of shares of the Company’s common stock. "We are co
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom